Growth in biologics and vaccines leading injectables business, Aptar Pharma

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Esben_H)
(Image: iStock/Esben_H)
Aptar Pharma is nearing completion of its US-based manufacturing site, as it continues to expand globally to keep pace with growth in the injectable drug delivery industry.

The expansion at Aptar Pharma’s manufacturing site at Congers, NY, enables the company to complete injectable elastomeric component manufacturing in the US for the first time, according to the company, including finishing operations for the company’s recently launched PremiumCoat™ coated stoppers.

The addition adds space for clean rooms and integrated vision equipment, which will be used to perform automatic inspection of all parts during the finishing process.

Construction is expected to be completed by the end of the first quarter of 2017.

A multiyear investment program

The expansion is part of a multi-year investment program to support the global growth of Aptar’s injectables business.

Anne Bailly, Product Communication Manager at Aptar Pharma told us the company is benefiting from growth in the injectable drug delivery industry.

Aptar Pharma's Congers, NY facility. (Picture courtesy of Aptar Pharma)
Aptar Pharma's Congers, NY facility. (Picture courtesy of Aptar Pharma)

According to Bailly, the production facilities of Brécey and Granville (France) also benefited from an investment plan to increase their production capacities to support business growth.

While our long-term objective was to establish a production facility closer to growing markets outside of Europe, our initial investment in capacity expansion was at Aptar Pharma’s existing facilities in Europe​,” said Bailly – which she explained allowed the company to better serve its existing customers and integrate new technology before expanding globally.

Market growth

Aptar Pharma expects a sustainable growth in the injectable market over the next five years – it also anticipates the demand for high quality components to expand geographically, including more emerging countries.

The growth in biologics and vaccines is leading to greater demand for prefilled syringes, cartridges and barrier solutions such as PremiumCoat​™,” Bailly said.

One of the strong drivers for the growth in the use of Pre-filled syringe and cartridges is the need for safe and convenient solutions, including the growing market demand for auto-injectors and pen injectors​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more